Ustekinumab Efficacy in Psoriatic Arthritis: 2 Year SUMMIT Trial Results

Save

615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks.

Ustekinumab Bests TNF Inhibitors for Biologic Survival in Psoriasis

Save

Using drug survival as a global measure of a drug's effectiveness, safety and tolerability, UK investigators used a national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register) to compare survival rates of the first biologic used in 3,523 biologic-naiv

Utility of Drug Levels and Anti-Drug Antibodies When Starting TNF inhibitors

Save

A prospective cohort of 331 patients tested for anti-adalimumab (n=160) and anti-etanercept (n-171) antibodies after initiation of their TNF inhibitor therapy.

FUTURE 2 Trial Shows Secukinumab to be Effective in Psoriatic Arthritis

Save

Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.

Fresolimumab (anti-TGF beta) Improves Systemic Sclerosis

Save

Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments.

IM Residents Concerned about Cost, But Don't Have Access to Cost of Care Numbers

Save

A large ACP survey of over 18,000 US internal medicine residents shows they often incorporate cost of care in discussions and decisions, but may not know the data (citation source http://buff.ly/1KeLq0D).

Adherence to ETN/MTX is Greater Than Triple DMARD Therapy

Save

Rheumatoid management hinges on choosing your best therapies first.

Australia Allows Pharmacy Substitution with Biosimilars Without Notice

Save

Biosimilars are copies of the biologic medicines used to treat inflammatory and immunologic conditions such as rheumatoid arthritis, multiple sclerosis and cancer- potentially at lower costs.

Chikungunya Infection in Rheumatoid Arthritis Patients

Save

The History of Citrullination

Save

1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times.  Dr.

NICE Judges Apremilast Less Cost Effective than TNF Inhibitors

Save

The National Institute for Heath and Care Excellence has turned down Otezla for coverage under the U.K. healthcare system for psoriatic arthritis.

Targeting Autoantibodies in Idiopathic Pulmonary Fibrosis

Save

Idiopathic pulmonary fibrosis carries a high mortality rate and can be a management challenge. Moreover, exacerbations of IPF may be fatal. A multicenter uncontrolled study examined the utility of targeting autoantibody production with revealed surprising results.

Frequency of Infliximab Infusion Reactions

Save

A Canadian registry shows that in community-based infusion clinics, infusion reactions to IFX are uncommon and mild to moderate in nature.

DSB: EULAR 2015 Safety Reports

Save

Biologic Use Curtails Sepsis Events. An analysis of the German biologics register, RABBIT, examined the effect of current biologic therapy on future risk of sepsis (#OP0161).

The EULAR 2015 Report – Friday and Saturday

Save

These abstracts and presentations were presented last week on the 12th and 13th of June at the EULAR 2015 annual meeting in Rome.

Expanding Global Biosimilar Market

Save

Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.

The EULAR 2015 Report- Friday

Save

These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.

The EULAR 2015 Report - Wednesday

Save

EULAR 2015 started the afternoon of Wednesday June 10th.

High Flare Rates with Drug Withdrawal in JIA

Save

While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.

Tofacitinib Equal to Etanercept in Psoriasis, but only at 10 mg bid Dose

Save

A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.